In particular, a study pointed out an improved survival benefit in rat orthotopic pancreatic cancer models treated with a combination of losartan and gemcitabine through a mechanism involving the inhibition of VEGF synthesis and suppression of PC cell proliferation via AT1R blockade [54]. This evidence concerns the gene VEGFA and familial pancreatic carcinoma.